Investigation of ErbB and Insulin Signaling Pathways in the Pathogenesis of Multiple Myeloma
Aim: Analysis of genes that play roles in multiple myeloma pathogenesis and their pathways are current research topics. We aimed to detect expression of some genes in ErbB and insulin signaling pathways. Methods: Bone marrow samples were taken from three healthy volunteers and 17 treatment-naiv...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Galenos Yayinevi
2018-06-01
|
Series: | Haseki Tıp Bülteni |
Subjects: | |
Online Access: | http://www.hasekidergisi.com/archives/archive-detail/article-preview/nvestigation-of-erbb-and-nsulin-signaling-pathways/18997 |
Summary: | Aim:
Analysis of genes that play roles in multiple myeloma pathogenesis and their pathways are current research topics. We aimed to detect expression of some genes in ErbB and insulin signaling pathways.
Methods:
Bone marrow samples were taken from three healthy volunteers and 17 treatment-naive patients. Firstly RNA isolation was made and then cDNA were synthesized. There are eight genes that are related to ErbB and insulin signaling pathways. Specific primers for these genes were designed. Gene expression analysis was performed by the real-time polymerase chain reaction method.
Results:
In the patient group, expressions of MTOR, RPTOR, PIK3CA, AKT1, ErbB4, PRKAR2A and PRKACB genes were detected to be 3-10 times up-regulated than in control group. There were no differences in the expression levels of RICTOR and GYS1 genes between control group and patient group. GYS1, PRKACB and PRKAR2A genes have been analyzed for the first time.
Conclusion:
In this study, PRKAR2A and PRKACB genes expressions were detected to be upregulated and this has not been reported in the literature before. MTOR, RPTOR, PIK3CA, AKT1, and ErbB4 genes expression were detected to be upregulated as has been reported in the literature. All these results will be useful to understand the pathogenesis of multiple myeloma. |
---|---|
ISSN: | 1302-0072 2147-2688 |